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ABSTRACT 
Introduction: Glucagon-like peptide-1 (GLP-1) 
has been the focus of considerable research 
activity in the treatment of type 2 diabetes 
mellitus (T2DM) because the incretin effect is 
significantly reduced or absent in individuals 
with T2DM. Thus, pharmacologic efforts to 
develop medications that mimic the actions of 
GLP-1 have become a target for improving or 
reversing chronic hyperglycemia. Two GLP-1 
receptor agonists are commercially available: 
exenatide twice daily (b.i.d.) and liraglutide 
once daily (q.d.). Targeted and individualized 
intensification of diabetes management can best 
be accomplished with a thorough understanding 
of these new medications. Methods:
Information was gathered through a search of 
MEDLINE and PubMed for GLP-1 and glycemic 
management in patients with type 2 diabetes. 
Results: Activation of the GLP-1 receptors on 
the β-cells results in enhanced levels of insulin 
biosynthesis, β-cell proliferation, resistance to 
β-cell apoptosis, and enhanced β-cell survival 
in both humans and rodents; yet, the risk of 
hypoglycemia is minimized because insulin 
production and exocytosis occurs in a glucose-
dependent manner. The efficacy and safety 
of the two commercially available GLP-1 
receptor agonists, liraglutide and exenatide, 
in managing postprandial glycemia have been 
well documented in numerous clinical trials, in 
which reductions in glycosylated hemoglobin 
(HbA1c) levels of −0.79% to −1.12% have been 
demonstrated. Weight reduction/maintenance 
and improvements in blood pressure and 
lipidemia have also been reported. Conclusion:
Because GLP-1 receptor agonists work in a 
glucose-dependent manner, they are likely 
to reduce hyperglycemia safely, without a 
marked fluctuation toward hypoglycemia. In 
the process of acutely restoring β-cell function, 
GLP-1 agonists may allow patients to achieve 
HbA1c <7% without experiencing weight gain 
or hypoglycemia. The ability of GLP-1 receptor 
agonists to improve blood pressure and 
postprandial lipidemia in the context of weight 30 Diabetes Ther (2011)  2(1):29-39.
neutrality or weight loss may have the potential 
to ameliorate some of the cardiovascular risks 
observed in patients with T2DM.
Keywords: cardiovascular risks; exenatide; 
gastric inhibitory polypeptide; glucagon-like 
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type 2 diabetes mellitus
INTRODUCTION
In the 1960s, data suggested that oral glucose 
elicited a much greater secretion of insulin 
than a similar amount of glucose administered 
intravenously,1 and that this potentiation of 
insulin secretion by the gut may be responsible 
for up to 70% of the insulin response to a meal.2,3 
This physiologic activity was subsequently 
referred to as the intestinal secretion of insulin, 
or incretin effect. It was later found that two 
hormones, gastric inhibitory polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1), are 
responsible for the incretin effect.3
GLP-1 and GIP have been the focus of 
considerable research activity in the treatment 
of type 2 diabetes mellitus (T2DM) because the 
incretin effect is significantly reduced or absent 
in people with T2DM.4 The reduced incretin 
effect is believed to contribute to impaired 
regulation of insulin and glucagon secretion in 
these patients.4
Although secretion of GIP remains relatively 
normal in T2DM subjects, its effect on insulin 
secretion is severely impaired.2,3 Conversely, 
despite the reduced secretion of GLP-1, its 
insulinotropic and glucagon-suppressive actions 
remain intact.2 In addition, there is a high 
concordance between the physiologic actions 
of GLP-1 and the therapeutic needs of patients 
with T2DM; the effects of GLP-1 on insulin and 
glucagon secretion following the ingestion of a 
meal are glucose dependent,3 thereby providing 
protection against hypoglycemia. Thus, 
pharmacologic efforts to develop medications 
that mimic the actions of GLP-1 have become a 
target for improving chronic hyperglycemia. 
Two GLP-1 receptor agonists are now 
commercially available: exenatide twice daily 
(b.i.d.) and liraglutide once daily (q.d.). When 
given by subcutaneous injection with pen 
devices, these medications become receptor 
bound and result in actions similar to the 
native hormone. Targeted and individualized 
intensification of diabetes management 
may best be accomplished with a thorough 
understanding of the currently available 
pharmacotherapeutic interventions. Clinicians 
should not only consider an agent’s mechanism 
of action, efficacy, safety, and tolerability, 
but also how to proactively address patient 
concerns related to the introduction of any 
new medication. The goal of this clinical review 
is to discuss the differences between the two 
medications in order to help clinicians make 
appropriate decisions regarding their use in 
patients with T2DM. 
THE PHYSIOLOGIC ACTIONS OF 
INCRETIN HORMONES
Both GIP and GLP-1 are secreted from gut 
endocrine cells in response to meals, and exert 
their actions by binding to structurally distinct 
receptors. The GIP receptor is predominantly 
expressed in pancreatic islet β-cells, whereas 
GLP-1 receptors are expressed in islet α- and 
β-cells, as well as in the central and peripheral 
nervous systems, heart, lung, kidney, and 
gastrointestinal tract.5
Activation of the GIP and GLP-1 receptors 
on the β-cells results in insulin production
and exocytosis in a glucose-dependent
manner (ie, only during hyperglycemia),
which minimizes risk of hypoglycemia.5Diabetes Ther (2011)  2(1):29-39. 31
Sustained activation of these receptors results in 
enhanced levels of insulin biosynthesis, β-cell 
proliferation, resistance to β-cell apoptosis, 
and enhanced β-cell survival in both humans 
and rodents.5 Table 1 presents the glucose 
homeostatic actions of both GIP and GLP-1 
in an euglycemic individual.2,5,6 Shortly after 
the incretin hormones are secreted, they are 
rapidly inactivated by dipeptidyl peptidase-4 
(DPP-4), leaving only 20% of the endogenously 
secreted GLP-1 to induce insulin secretion from 
pancreatic β-cells.7
Exogenous GLP-1 administered drugs and 
DPP-4 inhibitors have distinct mechanistic 
actions. The physiologic and pharmacologic 
effects of GLP-1 are based on the concentration 
of GLP-1 or a GLP-1 receptor agonist, as well as 
the affinity of receptor binding and number of 
receptors bound; the more receptors that are 
bound and activated, the greater the glycemic 
and nonglycemic responses to a given class of 
medications. The DPP-4 inhibitors, however, 
do not bind to GLP-1 receptors; rather, they 
prolong the half-life of endogenous GLP-1, 
thereby increasing GLP-1 levels.8 Thus, GLP-1 
agonists have greater effects on glycemic 
control, weight loss, and gastric emptying, 
compared with the DPP-4 inhibitors (ie, 
sitagliptin and saxagliptin), which are also 
commercially available.9
DIFFERENTIATING THE GLP-1 
AGONISTS
Successful treatment of T2DM requires an 
understanding of the disease pathogenesis, 
as well as a willingness to individualize and 
appropriately intensify therapy. As such, 
clinicians should always consider treatment as 
soon as possible, at as low a dose as possible, and 
as safely, as long, and as rationally as possible. In 
contrast to many other antidiabetic agents that 
increase the risk of hypoglycemia and/or weight 
gain, weight loss occurs with GLP-1 agonists 
while the risk of hypoglycemia is low, unless 
combined with an insulin secretagogue, such as a 
sulfonylurea. Within the class of GLP-1 agonists, 
multiple pharmacologic differences exist that 
may influence which medication is ultimately 
prescribed for a given individual. To address 
these differences, the two commercially available 
GLP-1 agonists—exenatide and liraglutide—will 
be discussed according to the systems that are 
affected by their use. 
Pharmacologic Profiles
Both exenatide b.i.d. and liraglutide, q.d. were 
developed to resist DPP-4 degradation and both, 
therefore, have a protracted mechanism of 
action. Exenatide shares 53% of its amino acid 
Table 1. Glucose homeostatic actions in an euglycemic individual.2,5,6
Action  GIP  GLP-1
Site of origination upon ingestion of food  K-cells of duodenum  L-cells of distal ileum and colon
Stimulates production and secretion of insulin from 
pancreatic β-cells in a glucose-dependent manner  Yes  Yes
Slows gastric emptying  No significant effect  Yes
Induces satiety, thereby reducing caloric intake  No significant effect  Yes
Inhibits glucagon secretion   No significant effect  Yes
Plasma glucose levels reduced in patients with T2DM2  No  Yes
Insulinotropic effect preserved in patients with T2DM2  No  Yes
GIP=gastric inhibitory polypeptide; GLP-1=glucagon-like peptide-1; T2DM=type 2 diabetes mellitus.32 Diabetes Ther (2011)  2(1):29-39.
sequence with native GLP-1.10 Exenatide has a 
time to peak plasma concentration (Tmax) of 2 to 
3 hours, a terminal elimination half-life (t½) of 
3.4 hours on day 1, with a corresponding peak 
plasma concentration (Cmax) of 163 pg/mL.11 
Exenatide must be injected subcutaneously 
b.i.d., within 60 minutes prior to a meal. 
By contrast, the degree of sequence identity 
between liraglutide and native GLP-1 is high, at 
97%.12 Although it has been speculated that self-
association is the primary mechanism behind 
the delayed absorption seen in liraglutide, 
reversible binding to albumin in the bloodstream 
and increased metabolic stability appear to be 
the basis for its prolonged half-life and delayed 
degradation by DPP-4.13 With a t½ of 11.6 to 12.8 
hours and a Tmax of 10 to 14 hours, liraglutide 
is suitable for q.d. dosing via subcutaneous 
injection, without regard for meals.14 
Exenatide is approved for monotherapy or 
as part of combination therapy (as an adjunct 
to diet and exercise). Exenatide is approved 
as an add-on to metformin, sulfonylurea, 
thiazolidinedione, a combination of metformin 
and sulfonylurea, or a combination of metformin 
and a thiazolidinedione. Liraglutide is indicated 
as monotherapy in patients who are metformin 
intolerant, or for patients in whom metformin 
may be contraindicated. Liraglutide may also 
be used in combination with metformin, 
metformin plus a sulfonylurea, metformin plus a 
thiazolidinedione (pioglitazone), or a sulfonylurea 
plus a thiazolidinedione. Patients using liraglutide 
in combination with a sulfonylurea should have 
the dose of the sulfonylurea reduced to minimize 
their risk of hypoglycemia.
Clinical Efficacy of Liraglutide and 
Exenatide 
The efficacy and safety of liraglutide and 
exenatide in clinical trials have been well 
documented in the Liraglutide Once Daily 
Compared with Exenatide Twice Daily (LEAD-6) 
study, a 26-week, randomized, open-label, 
parallel-group, multinational trial, conducted 
in 132 centers across 15 countries, including 
Europe and the United States.15 A total of 
464 patients with T2DM were randomized to 
receive liraglutide 1.8 mg q.d. subcutaneously 
or exenatide 10 μg b.i.d. subcutaneously, for 
26 weeks.15 All patients were maintained with 
background oral antidiabetic treatment, which 
included maximally tolerated doses of metformin 
and/or sulfonylurea.15 
The primary efficacy endpoint was change 
in glycosylated hemoglobin (HbA1c) value 
from baseline to week 26. Secondary efficacy 
endpoints included the proportion of patients 
reaching target HbA1c values (<7.0% and  6.5%), 
changes in fasting plasma glucose levels, self-
measured 7-point plasma glucose profiles, 
body weight, β-cell function, glucagon level, 
blood pressure, and lipid profiles.15 Results 
from the study indicate that liraglutide q.d. 
provides significantly improved glycemic 
control compared with exenatide b.i.d., with 
only minimal and transient adverse events 
(AEs) (Table 2).15 A reduction in HbA1c level was 
significantly greater with liraglutide (−1.12%), 
compared with exenatide (−0.79%; P<0.001).15 
In addition, a significantly greater proportion 
of patients receiving liraglutide compared with 
exenatide reached an HbA1c level of ≤7.0% (54% 
vs. 43%, respectively; P=0.0015), as well as an 
HbA1c level of ≤6.5% (35% vs. 21%, respectively; 
P<0.001).15
Significant reductions in fasting plasma 
glucose levels from baseline were also observed 
with liraglutide (−29 mg/dL) compared with 
exenatide (−11 mg/dL; P<0.001); postprandial 
glucose reductions after breakfast and supper 
were significantly greater with exenatide than 
with liraglutide (difference after breakfast of Diabetes Ther (2011)  2(1):29-39. 33
23.96 mg/dL, P=<0.001; difference after supper, 
18.2 mg/dL, P=0.005).15 The homeostasis model 
assessment of β-cell function (HOMA-B), which 
is utilized to quantify β-cell function, was 
significantly greater for the liraglutide group 
(32.12%) than with the exenatide group (2.74%; 
P<0.001).15 Changes in body weight were 
comparable and clinically meaningful with both 
medications (liraglutide –3.24 kg vs. exenatide 
–2.87 kg; P=0.224);15 approximately the same 
percentage of patients on each medication lost 
weight (liraglutide 78% vs. exenatide 76%).15 A 
significantly lower rate of minor hypoglycemia 
was observed with liraglutide (1.932 events) 
than with exenatide (2.600 events; P=0.013). 
The incidence of nausea was initially comparable 
between the two treatment groups, but was 
followed by a trend toward more rapid resolution 
of nausea in the liraglutide group, such that 
by week 26, only 3% of patients on liraglutide 
experienced nausea, versus 9% on exenatide 
(P<0.001).15
During a 14-week extension of the LEAD-6 
trial, patients switched from exenatide 10 μg 
b.i.d. to liraglutide 1.8 mg q.d., or continued 
on liraglutide 1.8 mg q.d.16 Overall, conversion 
from exenatide to liraglutide was well tolerated, 
and further improved parameters of glycemic 
control.16 More specifically, by study week 
40, patients who switched from exenatide to 
liraglutide experienced further and significant 
reductions in HbA1c levels (−0.32%; P<0.001), 
fasting plasma glucose (−16 mg/dL; P<0.001), 
and body weight (−0.9 kg; P<0.001).16 
Furthermore, patients who continued on 
liraglutide experienced further reductions in 
body weight (−0.4 kg).16 The greater efficacy of 
liraglutide may be secondary to sustained GLP-1 
receptor activation over 24 hours via q.d. dosing 
of liraglutide, compared with the biphasic levels 
that occur with the b.i.d. dosing schedule of 
exenatide.16 
From a clinical standpoint, clinicians should 
understand how to minimize the occurrence 
of nausea for either GLP-1 agonist. In many of 
the clinical trials, patients were “forced titrated” 
rapidly upwards towards the medication’s 
maximum therapeutic dose. If the patients 
Table 2. Comparison of liraglutide and exenatide on glycemic control in the LEAD-6 trial.15
  Liraglutide group*   Exenatide group†   
Outcome (vs. baseline values)  (n=233)  (n=231)  P value
Change in hemoglobin HbA1c (%)   −1.12  −0.79  <0.001
HbA1c <7.0% (% of pts)  54  43  <0.002
HbA1c ≤6.5% (% of pts)  35  21  <0.001
Change in fasting plasma glucose level (mg/dL)  −29  −11  <0.001
Change in body weight (kg)  −3.24  −2.87  0.224
HOMA-B‡ increase (%)  32.12  2.74  <0.001
Minor hypoglycemia 
(no. of events/subject-year)  1.932  2.600  0.013
*Liraglutide 1.8 mg q.d. + maximally tolerated stable doses of metformin, sulfonylurea, or both.
†Exenatide 10 µg b.i.d. + maximally tolerated stable doses of metformin, sulfonylurea, or both.
‡HOMA-B is the homeostatic model assessment of β-cell function and is used to quantify β-cell function. β-cell function can 
be estimated from fasting glucose and insulin levels. To calculate the per cent HOMA-B, the following formula was used:6 
HOMA-%B = (20 x fasting plasma insulin [mU/L]) ÷ (fasting plasma glucose [mmol/L] − 3.5)
HbA1c=glycosylated hemoglobin; HOMA-B=homeostatis model assessment-β-cell function.34 Diabetes Ther (2011)  2(1):29-39.
experienced any nausea they were offered few 
options other than continuing in the study, with 
the understanding that the nausea would be 
transitory, or simply withdrawing consent and 
dropping out of the study voluntarily. In five 
26-week registration trials, approximately 13% 
of liraglutide-treated patients experienced some 
nausea within the first 2 weeks; however, only 
2.8% of all subjects withdrew from these studies 
due to nausea.12 By comparison, in clinical trials 
of metformin, 25.5% of patients experienced 
nausea, compared with 8.3% who received 
placebo.17
The package inserts for exenatide and 
liraglutide do not provide suggestions for how 
to educate patients on minimizing nausea 
when initiating either medication. Therefore, 
we will provide several tools used in our clinical 
practices that may be helpful in counseling 
patients about management of nausea associated 
with exenatide and liraglutide.
Firstly, patients must be made aware that 
nausea is a very common adverse event (AE) with 
GLP-1 agonists. However, nausea, if it occurs, 
is likely to be transient and mild. Secondly, it 
should be explained to patients that GLP-1 
agonists make patients feel full. They may not 
feel hungry when using these medications. If 
they attempt to eat and challenge their satiety, 
nausea and vomiting will likely occur. Thirdly, 
if nausea does occur, the process of up-titration 
of medication dosages should be slowed down. 
More specifically, patients may remain on the 
exenatide 5-μg dose for longer than 1 month, or 
on the liraglutide 0.6-mg dose for longer than 
1 week, if necessary, before dose escalation. If a 
patient complains that the medication is causing 
excessive nausea or they refuse to continue using 
the medication for more than a few days, the 
patient should be evaluated for a possible eating 
disorder. In our experience, some patients with 
T2DM live to eat; any medication that minimizes 
their appetite would not be acceptable with their 
lifestyle and will be quickly rejected. 
Immunogenicity
GLP-1 analogs are peptides and, therefore, 
antibody formation may occur that potentially 
results in injection site reactions, loss of 
glycemic control, and anaphylaxis. In registry 
trials, antibodies that had a neutralizing effect 
on liraglutide in an in-vitro assay occurred in 
2.3% of the liraglutide-treated patients in a 
52-week monotherapy trial, and in 1.0% of the 
liraglutide-treated patients in 26-week add-on 
combination therapy trials; however, none of 
these individuals experienced deterioration of 
glycemic control.12
In the 30-week registry trials for exenatide, 
low titer antiexenatide antibodies, which did 
not affect glycemic control, were detected in 
38% of patients during the phase 3 development 
program.18 However, an additional 6% of patients 
had very high antibody titers at 30 weeks; half 
of these patients (3%) had an impaired glycemic 
response.18
From a clinical standpoint, the true significance 
of antibody induction is unclear. Antibodies to 
therapeutic proteins may compromise efficacy 
by neutralizing the medication and/or triggering 
AEs, ranging from mild injection site reactions 
to life-threatening anaphylaxis. Therapeutic 
proteins with higher structural similarity to 
endogenous proteins generally have a lower risk 
of both antibody formation and high antibody 
titer development.19 Liraglutide shares 97% 
homology to human GLP-1,12 compared with 
exenatide, which has 53% shared homology.10
In the LEAD-6 head-to-head study and 
the open-label extension arm, comparing the 
safety and efficacy of liraglutide and exenatide, 
antibody titers were obtained at weeks 0, 12, 26, 
40, 41, 78, and 79, prior to the administration Diabetes Ther (2011)  2(1):29-39. 35
of the daily dose.20 After 78 weeks on liraglutide, 
four (2.6%) of 154 patients had low-titer 
antibodies. In the four patients who developed 
neutralizing antibodies against liraglutide, 
HbA1c levels were reduced by up to 1.9% from 
baseline over the 78 weeks.20 After the 26-week 
exenatide study, 113 (61%) of 185 patients 
developed antibodies to the medication.20 Those 
patients who had “high titers” of neutralizing 
antibodies demonstrated a minimal reduction in 
their HbA1c level (−0.1%), compared with those 
individuals who had “low titers” of neutralizing 
antibodies, and were able to reduce their HbA1c 
by 1.0%.20 In the LEAD-6 extension protocol, 
1% of the liraglutide-to-liraglutide patients had 
injection site reactions, which were described as 
“irritation” at the injection site. Approximately 
2% of the exenatide-to-liraglutide patients 
experienced injection site reactions;20 75% of 
these reactions occurred when the exenatide 
antibody was positive.20 
All of the above adverse reactions were mild, 
and patients recovered and continued in the 
trial. The LEAD-6 trial, therefore, demonstrates 
that the presence of neutralizing antibodies 
may minimize the efficacy of a medication. 
However, patients with high antibody titers 
who were switched to liraglutide did not appear 
to experience a compromise in their glycemic 
response. For liraglutide-treated patients, the 
presence of neutralizing antibodies appears to 
have minimal clinical significance. 
Effects on Islet β-Cell Function 
In animal and in-vitro studies, incretin hormones 
have been shown to inhibit β-cell apoptosis and 
increase β-cell proliferation.21 Acutely, incretin 
therapy improves β-cell function and glycemia. 
With chronic use of incretin hormones, the 
potential exists to possibly reverse or stabilize 
the hyperglycemic disease process. 
In 2005, Fehse and colleagues demonstrated 
that patients with T2DM who were pretreated 
with a single intravenous infusion of exenatide, 
followed by a bolus injection of glucose, had a 
first-phase and second-phase insulin secretory 
pattern equal to that of healthy subjects.22 
Similar effects on β-cell stimulated insulin 
secretion were noted when liraglutide was 
injected subcutaneously.23 Interestingly, the 
liraglutide subjects had nearly normalized β-cell 
secretory output of insulin after a single injection 
of liraglutide, compared with individuals who 
received placebo.23
Longer-term effects of GLP-1 receptor agonists 
on  β-cell function have been studied with 
liraglutide. In a randomized controlled clinical 
trial, 39 patients with T2DM and a baseline HbA1c
of 8.1 to 8.5% (depending on the treatment group), 
were given liraglutide at doses of 0.65, 1.25, or 
1.9 mg per day versus placebo for 14 weeks.24
The HbA1c levels in the liraglutide patient groups 
decreased by 1.0% to 1.5%, compared with 
placebo (P<0.05).24 In addition, the 0.125 mg and 
1.9 mg doses of liraglutide increased first-phase 
insulin secretion, compared with placebo, by 
118% and 103%, respectively (P<0.05); second-
phase insulin response was significantly increased 
only in the liraglutide group receiving 1.25 mg 
per day (P=0.005 vs. placebo).24
To date, no human data have been presented 
to suggest that incretin-based therapy that 
protects or restores β-cell mass or function is 
durable. Thus, as in the case of exenatide, the 
restoration and improvement in β-cell function 
appears to be apparent only for as long as the 
medication is being utilized.25
Effects on Cardiovascular Markers
Positive effects on cardiovascular markers have 
been noted for both exenatide and liraglutide 
in multiple randomized, double-blind, placebo-36 Diabetes Ther (2011)  2(1):29-39.
controlled studies. However, there have been 
no studies establishing conclusive evidence of 
macrovascular risk reduction with any GLP-1 
agonist. Although meta-analysis of the six trials 
comparing liraglutide 1.8 mg q.d. with agents 
commonly used in the treatment of T2DM (ie, 
glimiperide, rosiglitazone, and insulin glargine)
and exenatide have assessed the impact of the 
incretin therapies on cardiovascular risk markers 
(Table 3), it is uncertain whether use of GLP-1 
agonists will have a substantial impact on 
cardiovascular outcomes.26 However, preliminary 
analysis of the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) study showed a 
75% reduction in mortality in exenatide-treated 
patients.27
Both liraglutide and exenatide exert a positive 
effect on blood pressure that appears to be 
independent of weight reduction. In one study 
evaluating the effects of ≥3 years of exenatide 
therapy in patients with T2DM (n=151), a 
sustained reduction in both diastolic blood 
pressure (mean change from baseline, –3.3 mmHg) 
and in systolic blood pressure (mean change from 
baseline, –3.5 mmHg) were reported.28 With 
liraglutide, systolic blood pressure reduction 
occurs to a greater extent than reduction in 
diastolic blood pressure. In one 14-week study, 
systolic blood pressure was significantly reduced 
by 5.2 mmHg (P=0.0417) to 7.9 mmHg (P=0.0023), 
compared with placebo, with a nonsignificant 
reduction in diastolic blood pressure.29 In another 
26-week study of liraglutide in combination with 
metformin and rosiglitazone, the systolic blood 
pressure was significantly (P<0.05) reduced in the 
liraglutide-treated groups (1.2 mg, –6.7 mmHg; 
1.8 mg, –5.6 mmHg), compared with placebo 
(–1.1 mmHg), with no change in diastolic blood 
pressure.26
The effects of the GLP-1 agonists on serum 
lipids are either neutral or beneficial with 
small, nonsignificant decreases in low-density 
lipoprotein (LDL-) cholesterol, increases in 
high-density lipoprotein (HDL-) cholesterol, 
and occasionally, significant decreases in fasting 
triglyceride levels (Table 3).30
The improvement in weight reduction 
with the use of GLP-1 agonists appears to 
Table 3. Effects of exenatide and liraglutide on cardiovascular risk markers.26
   Liraglutide  Exenatide  Placebo
   n=1363  n=231  n=524
Cardiovascular risk markers, relative change (%) 
  Brain natriuretic peptide  –11.9*  –3.9  1.4
  High-sensitivity C-reactive protein  –23.1†  –15.6*  –3.0
Lipids, change (mg/dL) 
  Total cholesterol  –2.3*  –0.9  0.2
  LDL-cholesterol  –3.6†  –2.7‡  –2.3‡
  HDL-cholesterol  –0.7†  –0.9*  –0.5‡
  Triglycerides  –3.6*  –0.9  –0.4
*P<0.01 vs. baseline.
†P<0.001 vs. baseline.
‡P<0.05 vs. baseline.
HDL=high-density lipoprotein; LDL=low-density lipoprotein.
Adapted with permission from: Plutzky J, Garber A, Falahati A, Taft AD, Paultzer NR. Reductions in lipids and CV risk 
markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. 20th World Diabetes Congress; October 18-22, 
2009; Montreal, Canada. Abstract O-0542. Available at: www.diabetes.ca. Accessed August 15, 2009.Diabetes Ther (2011)  2(1):29-39. 37
be superior to their overall ability to affect 
marked and consistent changes in lipid 
levels. Most importantly, the GLP-1 agonists 
have a significant effect on reducing lipemia. 
Mechanisms by which GLP-1 agonists tend 
to improve postprandial lipids would include 
their ability to delay gastric emptying,9 and to 
reinforce the ability of insulin to inhibit very low 
density lipoprotein-triglyceride production.31 
Safety
In the 30-week placebo-controlled clinical 
trials of exenatide, the most frequent AEs were 
nausea, hypoglycemia, vomiting, diarrhea, 
dizziness, headache, and dyspepsia.18 Nausea 
is usually mild or moderate, and decreases 
over time.18 Hypoglycemia is rare. Exenatide 
therapy should not be prescribed for patients 
with severe renal impairment or end-stage renal 
disease, and initiation of exenatide b.i.d. or dose 
escalation should be done cautiously in patients 
with moderate renal failure.18 Exenatide b.i.d. 
is not recommended for patients with severe 
gastrointestinal disease, such as gastroparesis.18 
Exenatide b.i.d. should be discontinued if a 
patient experiences a hypersensitivity reaction 
or develops pancreatitis.18 
The most common adverse reactions reported 
in ≥5% of patients treated with liraglutide, and 
reported more commonly than in patients 
treated with placebo, include headache, 
nausea, diarrhea, and anti-liraglutide antibody 
formation.12 Clinical trials have also shown 
that immunogenicity-related events, including 
urticaria and angioedema, were more common 
among liraglutide-treated patients (0.8%) than 
among comparator-treated patients (0.4%).12 
Transient nausea is usually mild to moderate 
and decreases over time, so that by week 26 
of the LEAD-6 study, 9% of exenatide-treated 
patients and 3% of liraglutide-treated patients 
continued to experience nausea.15 Hypoglycemia 
is rare. There is no dosage adjustment needed for 
patients with renal impairment.12
Patients with a personal or family history 
of medullary thyroid carcinoma (MTC) should 
not use liraglutide.12 MTC is an extremely rare 
form of thyroid cancer, with a prevalence rate of 
less than 600 new cases per year in the United 
States.32 In preclinical studies, liraglutide given 
to rodents in doses many times greater than 
the maximal doses anticipated in humans 
increased the incidence of C-cell tumors.32 
Similar increases in clinical markers and the 
development of C-cell tumors have been 
seen in rodent studies involving other GLP-1 
agonists, including exenatide, taspoglutide, and 
lixsenatide.6 In human volunteer studies, no 
link between liraglutide and C-cell tumors has 
ever been identified, and the United States Food 
and Drug Administration (FDA) determined 
that the risk of thyroid cancer among humans 
treated with liraglutide was low.32 GLP-1 receptor 
activation and expression appears to be species-
specific;6 20 months of liraglutide treatment 
at 60 times the normal human exposure levels 
failed to induce C-cell pathology in monkeys.6 
Mean calcitonin levels in patients exposed to 
liraglutide for 2 years also remained at the lower 
end of normal, when compared with placebo 
and comparator drugs in the clinical trials.6 
Elevated levels of calcitonin (>20 pg/mL) can 
be indicative of C-cell pathology in humans.6 
However, the FDA has indicated that monitoring 
calcitonin levels in liraglutide-treated patients is 
not recommended.32 
CONCLUSION
GLP-1 receptor agonists have been developed 
to address the direct pathophysiologic defects 
observed in T2DM. Because GLP-1 receptor 
agonists work in a glucose-dependent manner, 38 Diabetes Ther (2011)  2(1):29-39.
they are likely to reduce hyperglycemia 
safely, without a marked fluctuation toward 
hypoglycemia. In the process of acutely 
restoring β-cell function, GLP-1 agonists may 
allow patients to achieve HbA1c <7%, without 
experiencing weight gain or hypoglycemia. 
The safety and efficacy of this class of 
medications appears to be promising. Although 
no medication has been shown to be effective at 
reducing cardiovascular events, GLP-1 agonists 
are being studied in long-term clinical trials 
to determine whether they may play a role in 
reducing long-term cardiovascular mortality. The 
ability of GLP-1 receptor agonists to improve 
blood pressure and postprandial lipidemia in 
the context of weight neutrality or weight loss 
may have the potential to ameliorate some of 
the cardiovascular risks observed in patients 
with T2DM.
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